362 related articles for article (PubMed ID: 30322408)
1. Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology.
Teitsma XM; Yang W; Jacobs JWG; Pethö-Schramm A; Borm MEA; Harms AC; Hankemeier T; van Laar JM; Bijlsma JWJ; Lafeber FPJG
Arthritis Res Ther; 2018 Oct; 20(1):230. PubMed ID: 30322408
[TBL] [Abstract][Full Text] [Related]
2. Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy.
Teitsma XM; Jacobs JWG; Mokry M; Borm MEA; Pethö-Schramm A; van Laar JM; Bijlsma JWJ; Lafeber FPJ
Arthritis Res Ther; 2017 Jul; 19(1):170. PubMed ID: 28728565
[TBL] [Abstract][Full Text] [Related]
3. Explorative analyses of protein biomarkers in patients with early rheumatoid arthritis achieving sustained drug-free remission after treatment with tocilizumab- or methotrexate-based strategies: from transcriptomics to proteomics.
Teitsma XM; Jacobs JWG; Concepcion AN; Pethö-Schramm A; Borm MEA; van Laar JM; Bijlsma JWJ; Lafeber FPJG
Clin Exp Rheumatol; 2018; 36(6):976-983. PubMed ID: 29745885
[TBL] [Abstract][Full Text] [Related]
4. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported outcomes in newly diagnosed early rheumatoid arthritis patients treated to target with a tocilizumab- or methotrexate-based strategy.
Teitsma XM; Jacobs JWG; Welsing PMJ; Pethö-Schramm A; Borm MEA; Hendriks L; Denissen NHAM; van Laar JM; Lafeber FPJG; Bijlsma JWJ
Rheumatology (Oxford); 2017 Dec; 56(12):2179-2189. PubMed ID: 29029185
[TBL] [Abstract][Full Text] [Related]
6. Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies.
Teitsma XM; Jacobs JWG; Welsing PMJ; Pethö-Schramm A; Borm MEA; van Laar JM; Lafeber FPJG; Bijlsma JWJ
Rheumatology (Oxford); 2018 Feb; 57(2):309-317. PubMed ID: 29095992
[TBL] [Abstract][Full Text] [Related]
7. Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-II treat-to-target trials.
Verhoeven MM; de Hair MJ; Tekstra J; Bijlsma JW; van Laar JM; Pethoe-Schramm A; Borm ME; Ter Borg EJ; Linn-Rasker SP; Teitsma XM; Lafeber FP; Jacobs JW; Welsing PM
Ann Rheum Dis; 2019 Oct; 78(10):1333-1338. PubMed ID: 31196844
[TBL] [Abstract][Full Text] [Related]
8. Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study.
Akdemir G; Heimans L; Bergstra SA; Goekoop RJ; van Oosterhout M; van Groenendael JHLM; Peeters AJ; Steup-Beekman GM; Lard LR; de Sonnaville PBJ; Grillet BAM; Huizinga TWJ; Allaart CF
Ann Rheum Dis; 2018 Jan; 77(1):111-118. PubMed ID: 28970207
[TBL] [Abstract][Full Text] [Related]
9. Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors.
Teitsma XM; Jacobs JWG; Welsing PMJ; de Jong PHP; Hazes JMW; Weel AEAM; Pethö-Schramm A; Borm MEA; van Laar JM; Lafeber FPJG; Bijlsma JWJ
Ann Rheum Dis; 2018 Sep; 77(9):1261-1267. PubMed ID: 29760159
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety over 3 years after the 2-year U-Act-Early trial of the strategies initiating tocilizumab and/or methotrexate.
Verhoeven MMA; Tekstra J; Welsing PMJ; Pethö-Schramm A; Borm MEA; Bruyn GAW; Bos R; Griep EN; Klaasen R; van Laar JM; Lafeber FPJG; Bijlsma JWJ; de Hair MJH; Jacobs JWG
Rheumatology (Oxford); 2020 Sep; 59(9):2325-2333. PubMed ID: 31859346
[TBL] [Abstract][Full Text] [Related]
11. Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial.
Edwards CJ; Östör AJK; Naisbett-Groet B; Kiely P
Rheumatology (Oxford); 2018 Jan; 57(1):84-91. PubMed ID: 29155973
[TBL] [Abstract][Full Text] [Related]
12. Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study).
Kaneko Y; Kato M; Tanaka Y; Inoo M; Kobayashi-Haraoka H; Amano K; Miyata M; Murakawa Y; Yasuoka H; Hirata S; Tanaka E; Miyasaka N; Yamanaka H; Yamamoto K; Takeuchi T;
Ann Rheum Dis; 2018 Sep; 77(9):1268-1275. PubMed ID: 29853455
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial.
Burmester GR; Rigby WF; van Vollenhoven RF; Kay J; Rubbert-Roth A; Kelman A; Dimonaco S; Mitchell N
Ann Rheum Dis; 2016 Jun; 75(6):1081-91. PubMed ID: 26511996
[TBL] [Abstract][Full Text] [Related]
14. Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study).
Kaneko Y; Atsumi T; Tanaka Y; Inoo M; Kobayashi-Haraoka H; Amano K; Miyata M; Murakawa Y; Yasuoka H; Hirata S; Nagasawa H; Tanaka E; Miyasaka N; Yamanaka H; Yamamoto K; Takeuchi T
Ann Rheum Dis; 2016 Nov; 75(11):1917-1923. PubMed ID: 26733110
[TBL] [Abstract][Full Text] [Related]
15. Earlier is better when treating rheumatoid arthritis: but can we detect a window of opportunity?
Bergstra SA; Van Der Pol JA; Riyazi N; Goekoop-Ruiterman YPM; Kerstens PJSM; Lems W; Huizinga TWJ; Allaart CF
RMD Open; 2020 May; 6(1):. PubMed ID: 32471854
[TBL] [Abstract][Full Text] [Related]
16. Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study.
Glinatsi D; Heiberg MS; Rudin A; Nordström D; Haavardsholm EA; Gudbjornsson B; Østergaard M; Uhlig T; Grondal G; Hørslev-Petersen K; van Vollenhoven R; Hetland ML
Trials; 2017 Apr; 18(1):161. PubMed ID: 28376912
[TBL] [Abstract][Full Text] [Related]
17. Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE).
Smolen JS; Wollenhaupt J; Gomez-Reino JJ; Grassi W; Gaillez C; Poncet C; Le Bars M; Westhovens R
Arthritis Res Ther; 2015 Jun; 17(1):157. PubMed ID: 26063454
[TBL] [Abstract][Full Text] [Related]
18. Early DAS response after DMARD-start increases probability of achieving sustained DMARD-free remission in rheumatoid arthritis.
Verstappen M; Niemantsverdriet E; Matthijssen XME; le Cessie S; van der Helm-van Mil AHM
Arthritis Res Ther; 2020 Nov; 22(1):276. PubMed ID: 33228814
[TBL] [Abstract][Full Text] [Related]
19. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.
Smolen JS; Szumski A; Koenig AS; Jones TV; Marshall L
Arthritis Res Ther; 2018 Jan; 20(1):8. PubMed ID: 29338762
[TBL] [Abstract][Full Text] [Related]
20. Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY.
Boyapati A; Msihid J; Fiore S; van Adelsberg J; Graham NM; Hamilton JD
Arthritis Res Ther; 2016 Oct; 18(1):225. PubMed ID: 27716324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
